Approval · Notice of Compliance 29946 · 2023
BIMZELX: Notice of Compliance 29946
Issued January 16, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29946
- Date
- January 16, 2023
- Company
- Ucb Canada IncOakville, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a drug substance manufacturing and testing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BIMZELX | Not yet assigned | — |
Medicinal ingredients
- BIMEKIZUMAB 160 MG per ML
- BIMEKIZUMAB 160 MG per SYR